National lung cancer screening trial American college of radiology imaging network specimen biorepository originating from the contemporary screening for the detection of lung cancer trial (NLST, ACRIN 6654): Design, intent, and availability of specimens for validation of lung cancer biomarkers

Well annotated longitudinal samples were uniformly collected and stored in a central biorepository in the context of a screening trial, with a primary end point to determine whether screening for lung cancer with low-dose helical CT reduces mortality. The NLST ACRIN specimen bank represents a unique opportunity to complement imaging and validate early detection biomarkers for lung cancer. Biomarkers have the potential to improve diagnostic efficiency, reduce cost, and affect the evaluation and management of these patients. Although imaging has played an important role in diagnosing, staging, and following patients with lung cancer, new strategies using biomarkers offer alternative opportunities to address unresolved diagnostic issues in oncology.